NEW YORK CITY, NY / ACCESS Newswire / May 2, 2025 / In an era where healthcare is as much about timely access and ...

Seasonique (0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol pills, 0.01 mg and ethinyl estradiol pills) (DIN 02346176) ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy. If approved, the pill ...

A decision is expected in the fourth quarter of 2025.

SETWorks, a leading software provider for disability service agencies and human services providers, has secured a strategic growth investment from Polaris Growth Fund ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...